Highlights
- Gedeon Richter has agreed to propose a cash Acquisition at AUD 6.40 per Mayne Pharma share.
- The proposed scheme values Mayne Pharma's Equity at approximately AUD 604 million.
- Mayne's board supports the proposal subject to an independent expert and no superior offer.
- Completion depends on approvals and a separate international-business divestment.
Mayne Pharma Group (ASX:MYX) develops and commercialises specialty pharmaceutical products, with activities centred on women's health and dermatology. The Australian-listed company’s latest corporate development is a proposed acquisition by Hungarian pharmaceutical group Gedeon Richter. The agreement, announced in November 2026, sets out a cash consideration for shareholders but remains conditional on several transaction steps, including regulatory and Shareholder approvals.
Mayne Pharma Sets Out Cash Scheme Terms
Mayne Pharma (ASX:MYX) announced on 17 November 2026 that it had entered a scheme implementation deed under which Richter would acquire all its shares for AUD 6.40 each in cash. The company stated that the proposed consideration values its equity at approximately AUD 604 million. These figures describe the proposed transaction, not cash already received by shareholders. Completion would depend on implementation of the scheme under the agreed terms.
The proposal is structured as a scheme of arrangement, a process requiring a shareholder vote and court approval. A scheme booklet would normally provide shareholders with the independent expert's assessment, timetable and detailed conditions. Until implementation, Mayne Pharma (ASX:MYX) remains a separately listed company and its existing operations continue.
Why Richter Is Pursuing the Pharmaceutical Business
Richter operates internationally across several pharmaceutical categories, including women's health. Mayne Pharma's US-focused women's health and dermatology activities would provide an established commercial platform within that area. The proposed transaction therefore concerns the combination of complementary pharmaceutical operations rather than a near-term change to the medicines themselves.
The two companies also have different geographic footprints. Richter has an international research, Manufacturing and commercial network, while Mayne Pharma (ASX:MYX) has developed specific specialty-medicine franchises and US Marketing capabilities. Any integration approach would be determined after closing; the announcement should not be interpreted as confirmation of future product launches, staffing changes or manufacturing decisions.
Board Recommendation and Conditions
The Mayne Pharma board unanimously recommended that shareholders vote in favour, provided no superior proposal emerges and an independent expert concludes, and continues to conclude, that the scheme is in shareholders' best interests. This recommendation is conditional, not a guarantee of transaction completion.
The arrangement also depends on regulatory and court processes and on completing Mayne's proposed international-business sale to Evaris Pharma. That separate divestment has its own approval requirements. Consequently, Mayne Pharma (ASX:MYX) faces multiple interdependent transaction milestones. A delay or failure in one required step could affect the timing or completion of the wider scheme. The ultimate outcome remains subject to formal decisions rather than management intentions alone.
What Happens Before Completion
The next substantive documents are the scheme booklet and the independent expert's report. Shareholders would then have the opportunity to assess the terms and vote at a scheduled meeting. Relevant regulators and the court must also consider the transaction before it can be implemented.
For Mayne Pharma (ASX:MYX), the distinction between agreement and completion is important. The announced cash price is fixed in the proposed scheme, but the payment is contingent on all required conditions being satisfied or appropriately waived. The company’s existing commercial activities, regulatory obligations and pharmaceutical Supply arrangements remain relevant while that process continues. No operating synergies or post-acquisition outcomes should be treated as established before they are disclosed.
Key Insights
Mayne Pharma's proposed acquisition would transfer ownership of its specialty pharmaceutical operations to Richter if the scheme becomes effective. The AUD 604 million indicative equity value and AUD 6.40 cash consideration are established transaction terms; completion remains dependent on the expert's assessment, shareholder approval, court process, regulatory clearance and the separate divestment.






Please wait processing your request...